At the time of writing, Enliven Therapeutics Inc [ELVN] stock is trading at $432420.0, up 518194%. An important factor to consider is whether the stock is rising or falling in short-term value. The ELVN shares have gain 8.34% over the last week, with a monthly amount glided 22.55%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Enliven Therapeutics Inc [NASDAQ: ELVN] stock has seen the most recent analyst activity on June 16, 2025, when Goldman initiated its Buy rating and assigned the stock a price target of $37. Previously, BTIG Research started tracking the stock with Buy rating on December 13, 2024, and set its price target to $42. On September 09, 2024, H.C. Wainwright initiated with a Buy rating and assigned a price target of $37 on the stock. Robert W. Baird started tracking the stock assigning a Outperform rating and suggested a price target of $32 on June 11, 2024. Mizuho initiated its recommendation with a Buy and recommended $34 as its price target on April 09, 2024. Jefferies started tracking with a Buy rating for this stock on March 29, 2023, and assigned it a price target of $27.
For the past year, the stock price of Enliven Therapeutics Inc fluctuated between $13.30 and $30.03. Currently, Wall Street analysts expect the stock to reach $45.5 within the next 12 months. Enliven Therapeutics Inc [NASDAQ: ELVN] shares were valued at $432420.0 at the most recent close of the market. An investor can expect a potential drop of -99.99% based on the average ELVN price forecast.
Analyzing the ELVN fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.31, Equity is -0.32 and Total Capital is -0.38.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
It is important to note that Enliven Therapeutics Inc [NASDAQ:ELVN] has a current ratio of 21.06. On the other hand, the Quick Ratio is 21.06, and the Cash Ratio is 7.28.
Transactions by insiders
Recent insider trading involved Lyssikatos Joseph P, Officer, that happened on Jun 20 ’25 when 12500.0 shares were purchased. PRESIDENT AND CEO, Kintz Samuel completed a deal on Jun 17 ’25 to sell 12500.0 shares. Meanwhile, CHIEF FINANCIAL OFFICER Hohl Benjamin sold 3000.0 shares on Jun 13 ’25.
